大健康产业

广义指对人类健康直接和间接产生影响的相关产业,一般指与人类健康相关的主要产业,如医疗、康复、医药、保健品、化妆品、医疗器械等相关产业。目特指保健品、化妆品和家用健康器械产业。

新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 大健康产业 » 强生创新中心全球达成12个新联盟——引爆早期科学和新技术创新合作

强生创新中心全球达成12个新联盟——引爆早期科学和新技术创新合作

来源:生物谷 2014-06-20 09:36

2014年6月20日讯 /生物谷BIOON/ --强生(JNJ)6月19日宣布,与遍布全球的生命科学公司和科研机构达成了12个新的联盟,在广泛的治疗领域及横跨制药、医疗设备、诊断、消费保健领域探索早期创新。强生首席科学官及全球制药主席Paul Stoffels称,未来的医药保健将由制药公司、学术机构和政府部门共同定义,三方共同合作并充分利用现有的优势,在思考当前模式的同时,尝试新方式的创新。

自一年多前推出以来,强生创新中心正与全球生命科学研究者和企业家共同合作,鉴定激动人心的早期技术,并将其转化为患者的解决方案。

今日公布的早期合作,代表了由波士顿、加州、伦敦创新中心近期的研发联盟,同时也包括激动人心的新技术,比如3D打印技术用于骨科创伤,创造新的棕色脂肪用于代谢性疾病,推进医疗需求显著未获满足的疾病领域中的新科学,如淋巴瘤、类风湿性关节炎、前列腺癌、痴呆症、阿尔茨海默氏症、糖尿病、失眠。

合作包括:

1、利用有前途的新方法来治疗癌症:

针对淋巴瘤——杨森生物技术公司和强生创新(JNJ Innovation)已与威尔康奈尔医学院(Weill Cornell Medical College)达成合作,开发化合物靶向引起淋巴瘤的一种蛋白。

新型免疫疗法治疗前列腺癌——杨森生物技术公司和强生创新(JNJ Innovation)已与Aduro 生物技术公司达成全球独家授权,开发新型免疫疗法治疗前列腺癌。

2、患者特异性3-D打印用于骨科需求:

3-D打印可吸收植入物——DePuy公司和强生创新与医疗设备商Tissue Regeneration Systems(TRS)公司达成战略合作,帮助开发患者特异性、可吸收植入物,用于创伤和矫形外科肿瘤学中的大段骨缺损治疗。此次合作将把DePuy的专有技术和市场领导地位与TRS的3D打印技术和开发专长进行配伍。该合作还包括一系列其他应用的发展机遇。

3、推进阿尔茨海默氏症和神经科学进展:

加快老年痴呆症的研究进展——杨森研发公司神经科学将于英国Dementias Research Platform(痴呆症研究平台,DRP)合作。DRP是英国Medical Research Council(医学研究委员会,MRC)的重要举措,旨在通过与6个公司及8个领先学术机构的协调公-私合作伙伴关系,加速痴呆症的研究进展。

感应镇静层面——强生旗下Ethicon Endo-Surgery公司已与BrainStem Biometrics公司达成研究合作,将共同出资确定一种小型、非侵入性医疗设备传感器Tremor Monitor Unit的临床和操作可用性,该传感器可用于正在接受麻醉的患者,检测分钟眼球运动。作为基础脑干功能的一种可能的生物标志物,该技术具有区分镇静安全和不安全水平的潜力。

失眠——杨森制药、强生创新、杨森研发公司神经科学与Minerva Neurosciences达成研究合作,开发一种食欲素-2受体拮抗剂MIN-202,用于原发性和继发性失眠及其他相关神经疾病的治疗。

中枢神经系统的表观遗传学调节——强生开发公司已参与Rodin Therapeutics与强生创新的A系列股权投资,Rodin致力于发现表观遗传学调制器,用于认知障碍(包括阿尔茨海默氏症)的治疗。

4、寻求新颖方法治疗糖尿病和心血管疾病:

创造新的棕色脂肪——杨森制药和强生创新已与Energesis制药达成合作,鉴定可刺激形成棕色脂肪(BAT)的生物化合物,用于代谢性疾病的治疗。Energesis公司的新颖方法利用了近年来在BAT生物学中的科学发现,增强机体燃烧所储存脂肪的能力,降低胰岛素抵抗。

营养-感应通路——强生开发公司已参与Navitor制药和强生创新的股权投资。Navitor正在开发高度特异性mTORC1调节子,该通路主要负责细胞对可利用养分的反应,包括细胞生长和功能。Navitor正利用mTORC1通路的核心重要地位,开发新的疗法,用于代谢性疾病,如糖尿病,以及自身免疫、肌肉骨骼及其他疾病领域。

心脏重塑——强生开发公司已参与Ascelegen Therapeutics和强生创新的股权投资。Ascelegen正在开发新颖的治疗相关生长因子用于心血管疾病,包括心脏衰竭。Ascelegen的工作建立于哈佛干细胞研究所和布里格姆-妇女医院联合开展的GDF-11研究。

5、针对自身免疫性疾病:

终止类风湿性关节炎和其他自身免疫性疾病中自身抗原(autoantigen)的产生——强生开发公司已参与Padlock Therapeutics和强生创新的股权投资。Padlock正在开发靶向蛋白精氨酸脱亚氨酶(介导蛋白瓜氨酸化的一类酶)的新颖疗法。蛋白瓜氨酸化可导致强劲自身抗原的产生,参与导致类风湿性关节炎的最早期事件,并驱动活动性自身免疫性疾病的炎症和免疫复合物的形成。

6、皮肤、口腔和呼吸疾病领域的新战略:

探索微生物组(Microbiome)对健康和疾病的影响——强生消费品公司和强生创新已与英国曼彻斯特大学达成合作,探索益生菌提取物用于预防和治疗皮肤、口腔、呼吸疾病的应用潜力。该协议突出了强生创新在横跨制药、医疗器械、诊断和消费业务领域创建科研合作的方法。

去年,强生创新(JNJ Innovation)已推出了创新中心,建立了4个区域枢纽,以确定具有推进新医疗解决方案潜力的科学机会。通过创新中心,外部创新者能够获得强生内部广泛的资源,包括资金、研发专业知识和孵育。目前,在波士顿、伦敦和加州的办事处已全面运作,位于中国上海的第4个办事处目前已组建了一个小型但不断增长的科学团队,将于2014年正式开放,在整个亚太地区展开研发合作。生物谷Bioon.com)

英文原文:Johnson & Johnson Innovation Catalyzes New and Exciting Science and Technology in Pharmaceutical, Medical Device, Diagnostic and Consumer Healthcare Spaces

Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer’s, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics for skin infections

New Brunswick (June 19, 2014) – Johnson & Johnson Innovation, LLC today announced 12 new alliances with life science companies and research institutions around the globe to explore early-stage innovation in a broad range of therapeutic areas and across pharmaceuticals, medical device and diagnostics and consumer healthcare.

“The future of healthcare will be defined by companies, academic institutions and governments that collaborate to leverage existing strengths, while at the same time think outside current paradigms and experiment with new ways of innovating,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Pharmaceuticals. “By being where these new frontiers in science and technology are being forged, our goal is to translate these insights into promising treatments for the future.”

Launched more than a year ago, the Johnson & Johnson Innovation centers are working globally with life science researchers and entrepreneurs to identify exciting early-stage technologies and translate them into solutions for patients.

The early-stage collaborations announced today represent recent research and development alliances facilitated by the Boston, California and London innovation centers and include exciting technologies like 3-D printing for orthopaedic trauma, creating new brown fat for metabolic diseases and advancing novel science in areas of significant unmet medical need such as lymphoma, rheumatoid arthritis, prostate cancer, dementia, Alzheimer’s, diabetes and insomnia.

“The broad variety of the collaborations we are announcing today, and the unique ways in which we are working with our collaborators, illustrates our strong commitment to being flexible and creative in our deal making in order to maximize the potential of each individual technology,” added Dr. Stoffels. “Our goal is to enrich the life science ecosystem on a global scale by redefining the R&D paradigm.”

The collaborations include:

Promising New Ways to Treat Cancer

Targeting Lymphoma – Janssen Biotech, Inc. and Johnson & Johnson Innovation have formed a research collaboration with Weill Cornell Medical College aimed at developing compounds for targeting the function of a lymphoma causing protein. Through the collaboration, investigators at Weill Cornell and Janssen drug development researchers will collaborate to discover, validate and characterize inhibitors of the protein and further elucidate novel targeting methods.
Novel Immunotherapies for Prostate Cancer – Janssen Biotech, Inc. and Johnson & Johnson Innovation have obtained an exclusive, worldwide license from Aduro BioTech to certain product candidates specifically engineered for the treatment of prostate cancer. In a separate transaction, Johnson & Johnson Development Corporation participated in a Series C equity round raised by Aduro.
Patient-Specific 3D Printing for Orthopedic Needs

3-D Printing Resorbable Implant – DePuy Synthes Products, LLC and Johnson & Johnson Innovation have formed a strategic collaboration with the medical device company Tissue Regeneration Systems, Inc. (TRS) to help develop patient-specific, resorbable implants for large bone segmental defect treatment in trauma and orthopaedic oncology. The collaboration matches DePuy Synthes’ expertise and market leadership with TRS’s 3-D printing technologies and development expertise. The collaboration also includes potential future development opportunities in a range of additional applications within DePuy Synthes’ areas of strategic interest.
Advancing Progress on Alzheimer’s Disease and Neuroscience

Accelerating Progress on Dementia Research – Through an agreement facilitated by Johnson & Johnson Innovation, the neuroscience therapeutic area of Janssen Research & Development, LLC will participate in the U.K. Dementias Research Platform. The Platform is a major initiative of the Medical Research Council that seeks to accelerate progress in dementias research through a coordinated public-private partnership with six industry and eight leading academic institutions.
Sensing Sedation Levels – Ethicon Endo-Surgery Inc., a member of the Johnson & Johnson Family of Companies, has entered into a research collaboration and option agreement with BrainStem Biometrics Inc. through a deal facilitated by Johnson & Johnson Innovation. As part of the collaboration, Ethicon will co-fund studies to confirm the clinical and operational utility of BrainStem Biometrics’ Tremor Monitor Unit, a small, non-invasive medical device biosensor that is used to detect minute eye movements in patients undergoing anesthesia. As a likely marker of basic brainstem function, this technology has the potential to distinguish between safe and unsafe levels of sedation for patients around the world.
Putting Insomnia to Rest – Janssen Pharmaceutica N.V., Johnson & Johnson Innovation and the Janssen neuroscience therapeutic area have established a research collaboration with Minerva Neurosciences, subject to certain conditions, around the development of an orexin-2 antagonist, MIN-202. The program will focus on the treatment of patients with primary and secondary insomnia and potentially other related neuropsychiatric disorders.
Epigenetic Modulators in the CNS – Johnson & Johnson Development Corporation participated in the Series A equity investment of Rodin Therapeutics in collaboration with Johnson & Johnson Innovation. Rodin is dedicated to finding epigenetic modulators for the treatment of cognitive disorders, including Alzheimer’s disease.
Seeking Novel Approaches to Treat Diabetes and Cardiovascular Disease

Creating New Brown Fat – Janssen Pharmaceuticals, Inc. and Johnson & Johnson Innovation have established a collaboration with the biotechnology company Energesis Pharmaceuticals, which is identifying biological compounds that stimulate the formation of brown fat (BAT) for use in treating metabolic diseases. The company’s approach is a novel strategy leveraging recent scientific insights in BAT biology to increase the body’s ability to burn stored fat and lower insulin resistance.
Taking On the Nutrient-Sensing Pathway – Johnson & Johnson Development Corporation has made an equity investment in Navitor Pharmaceuticals in collaboration with Johnson & Johnson Innovation.  Navitor is developing highly specific modulators of mTORC1, the pathway primarily responsible for cells’ response to nutrient availability including cell growth and function. Navitor is leveraging the central importance of the mTORC1 pathway to develop new therapies for metabolic diseases, like diabetes, as well as autoimmune, mulsculoskeletal and other disease areas.
 
Cardiac Remodeling – Johnson & Johnson Development Corporation has made an equity investment in Ascelegen Therapeutics in collaboration with Johnson & Johnson Innovation. Ascelegen is working on developing novel growth factor related therapies for cardiovascular diseases, including heart failure. Ascelegen’s work builds on GDF-11 research conducted at the Harvard Stem Cell Institute and the Brigham and Women's Hospital.
Targeting Autoimmune Disease

Halting Autoantigen Production in Rheumatoid Arthritis and Other Autoimmune Diseases – Johnson & Johnson Development Corporation participated in a Series A equity investment in Padlock Therapeutics in collaboration with Johnson & Johnson Innovation. Padlock is a company that is developing new therapies targeting the protein arginine deiminases, a class of enzymes that mediate protein citrullination. Protein citrullination leads to the creation of potent autoantigens implicated in the very earliest events that lead to rheumatoid arthritis and drives inflammation and immune complex formation in active autoimmune disease.
New Strategies for Skin, Oral and Respiratory Conditions

Exploring the Microbiome’s Impact on Health and Disease – Johnson & Johnson Consumer Companies, Inc. and Johnson & Johnson Innovation have established a collaboration with scientists from The University of Manchester to explore potential applications of probiotic extracts for prevention and treatment of skin, oral and respiratory conditions. The agreement underscores the approach Johnson & Johnson Innovation is taking to establish scientific collaborations in areas that span its pharmaceutical, medical device and diagnostics and consumer businesses.
Johnson & Johnson Innovation launched the innovation centers last year, establishing four regional hubs to identify scientific opportunities with the potential to advance the development of new healthcare solutions. Through the innovation centers, external innovators have access to a broad range of resources within Johnson & Johnson, including funding, R&D expertise and incubation at one of the company’s four Janssen Labs facilities. Today, there are fully operational offices in Boston, London and California, and a fourth location in Shanghai now houses a small, growing scientific team and will officially open this year to develop collaborations across the Asia Pacific region.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


...(全文约12935字)
显示全文...
<< 去看24小时最新(39)

相关标签

最新会议 培训班 期刊库